Management of Itching on Entresto
If a patient develops itching while taking Entresto (sacubitril/valsartan), first determine if this represents simple pruritus or angioedema, as the latter requires immediate discontinuation; for isolated itching without angioedema, attempt symptomatic management with antihistamines, but if pruritus persists and significantly impacts quality of life despite treatment, discontinue Entresto as this is a recognized adverse effect that resolves upon cessation.
Initial Assessment: Rule Out Angioedema
The FDA label for Entresto clearly distinguishes between simple itching and angioedema 1. You must immediately assess for:
- Facial, lip, or tongue swelling
- Laryngeal involvement (voice changes, difficulty swallowing, stridor)
- Respiratory compromise
If any signs of angioedema are present, discontinue Entresto immediately and permanently 1. Angioedema occurred in 0.5% of patients in PARADIGM-HF, with a notably higher rate of 2.4% in Black patients 1. This is a contraindication to re-challenge.
Management of Isolated Pruritus
Step 1: Symptomatic Treatment Trial
For itching without angioedema, the British Association of Dermatologists guidelines recommend that drug-induced pruritus should prompt a trial of medication cessation, but only if the risk-benefit analysis is acceptable 2. Given Entresto's mortality benefit in heart failure, initial symptomatic management is reasonable:
- Trial antihistamines first - The FDA label notes that antihistamines have been useful in relieving symptoms when angioedema is confined to face and lips 1
- Monitor closely for 2-4 weeks to assess response
Step 2: Consider Discontinuation Based on Quality of Life
Critical caveat: A 2021 case series documented three patients (ages 58-73) who developed persistent nasal pruritus specifically with sacubitril/valsartan that did not respond to antihistamines 3. All three patients discontinued the medication within 3-6 months due to quality-of-life impact, with complete resolution of symptoms afterward 3.
If itching persists despite antihistamines or significantly impairs quality of life, discontinue Entresto 2, 3. The principle for drug-induced itch management is discontinuation of the causative agent 4.
Alternative Considerations
Before attributing itching solely to Entresto:
- Review all concurrent medications - Valsartan alone (the ARB component) has been reported to cause pruritic exanthematous eruptions 5, 6
- Assess for other causes: Check for rash, evaluate renal function (uraemic pruritus), liver function (cholestatic pruritus), and consider other systemic causes 2
- Examine for skin lesions - Drug-induced itch is defined as generalized itching without skin lesions 4
Key Clinical Pitfalls
- Do not confuse simple pruritus with early angioedema - Any facial swelling mandates immediate discontinuation
- Black patients have 5-fold higher angioedema risk (2.4% vs 0.5%) - maintain heightened vigilance 1
- Prior ACE inhibitor or ARB-related angioedema is an absolute contraindication to Entresto 1
- Quality of life matters - While Entresto reduces mortality and hospitalization 7, 8, persistent pruritus that antihistamines cannot control justifies discontinuation, as documented in real-world cases 3
When to Continue vs. Discontinue
Continue Entresto if:
- Itching is mild and controlled with antihistamines
- No signs of angioedema develop
- Patient tolerates symptoms without quality-of-life impairment
Discontinue Entresto if:
- Any angioedema develops (mandatory) 1
- Persistent pruritus unresponsive to antihistamines 3
- Significant quality-of-life impairment 3
The decision balances Entresto's proven 30% reduction in cardiovascular death or HF hospitalization 7 against the patient's symptom burden. However, medication adherence requires tolerability - persistent bothersome symptoms will lead to discontinuation regardless, as demonstrated in the case series 3.